Market Overview

UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT for NewLink Genetics

Related NLNK
Momentum Stocks Showing Weakness
UPDATE: Mizuho Securities USA Initiates Coverage On NewLink Genetics Corp On Emerging Market Pure Play

In a company update published earlier today, Cantor Fitzgerald L.P. reiterated its Buy rating for NewLink Genetics Corporation (NASDAQ: NLNK) and raised its price target from $15.00 to $18.00.

Cantor Fitzgerald went on to say “We have identified what we believe to be critical success factors for a cancer immunotherapy company and further believe that NewLink meets these criteria. The company has identified appropriate clinical settings with which to test its technology (modest disease burden, consistent booster dosing), has a robust trial design, is addressing critical unmet medical needs, and has a scalable, financially reasonable manufacturing process and technology. Additionally, the stage and depth of NewLink's clinical program is compelling, in our view, and there are multiple opportunities for milestone updates over the next 24 months. We are particularly encouraged by the Phase II HyperAcute Pancreas study as two- and three-year disease free and overall survival showed a strong and sustained response to the vaccine in a statistically significant manner.”

NewLink Genetics Corporation closed yesterday at $12.41.

Latest Ratings for NLNK

DateFirmActionFromTo
Sep 2014Mizuho SecuritiesInitiates Coverage onBuy
May 2014Stifel NicolausMaintainsBuy
Mar 2014McNicoll Lewis VlakMaintainsBuy

View More Analyst Ratings for NLNK
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (NLNK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters